ClinicalTrials.gg
Not yet recruitingNCT05718167Updated Feb 14, 2023

TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.

A Phase 3 interventional study of TQB2450 and Anlotinib hydrochloride capsule in Advanced Squamous Non-Small Cell Lung Carcinoma, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Not yet recruiting at 4 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-02-14.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years 1 month ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
570
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing benmelstobart in Carcinoma, Non-Small-Cell Lung — 9 open to participants now, 9 under way, 2 of them phase 3. benmelstobart · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
Largest of 14
570 · median 154
Started
2023
with 3 others
Phase 3
5 of 14
2 open now
Registered
6th of 14
by date
Lead sponsor
7 of 14
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Among the 14 studies testing benmelstobart in Carcinoma, Non-Small-Cell Lung, this one has the largest planned enrollment, is one of 4 that started in 2023, is one of 5 in phase 3, and was the 6th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

9 of the 14 studies testing benmelstobart in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

About benmelstobart

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing benmelstobart in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is Phase 3, randomized, double-blind, parallel controlled study designed to evaluate the Progression Free Survive (PFS) of TQB2450 injection combined with Paclitaxel Injection and Carboplatin Injection Followed by TQB2450 injection combined with Anlotinib Hydrochloride Capsules versus Tislelizumab injection combined with Paclitaxel Injection and Carboplatin Injection followed by Tislelizumab injection in locally advanced (stage ⅢB/ⅢC) and metastatic or recurrent (Stage IV) squamous NSCLC subjects.The primary endpoint is PFS assessed by IRC.

03

Conditions studied

  • Advanced Squamous Non-Small Cell Lung Carcinoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • According to the 8th edition of the International Association for the Study of Lung Cancer and the American Joint Committee on Cancer Classification, the Tumour, node and (TNM) staging of lung cancer is locally advanced (stage ⅢB/ⅢC), metastatic or recurrent ( Stage IV) NSCLC patients.
  • Between the ages of 18-75 years (calculated based on the date of signing ICF); male or female; (ECOG) score 0-1; estimated survival time ≥ 3 months.
  • According to the 1.1 standard, there is at least one . If the measurable lesion is located in the radiotherapy area, it should be clearly defined as a progressive state.
  • Patients who have not received systemic anti-tumor therapy for advanced, recurrent or metastatic diseases in the past. For those who have received chemotherapy in the past, the interval between the recurrence time and the last adjuvant chemotherapy should be at least 6 months; The interval between the end of previous radiotherapy for chest and this treatment should be more than 6 months, and the interval between palliative radiotherapy for chest and this treatment should be more than 7 days.
  • Tumor tissue sections that have not undergone radiotherapy at or after the diagnosis of advanced or metastatic NSCLC must be provided.These are Used for expression detection.Tumor tissue samples must be archived samples or freshly obtained samples within 12 months before randomization.
  • main organ function is good, meet the following standards.

    1. Routine blood examination standards (without blood transfusion or correction with hematopoietic stimulating factor drugs within 14 days before screening):

      1. (ANC) ≥1.5×109 /L;
      2. ≥100×109 /L;
      3. ≥90 g/L.
    2. The blood biochemical examination shall meet the following standards:

      1. Total (TBIL) ≤ 2 × (ULN) (Patients with Gilbert syndrome ≤ 3 × ULN);
      2. (ALT) and aspartate aminotransferase (AST)≤2.5×ULN. If it is accompanied by liver metastasis, ALT and AST≤5×ULN;
      3. Serum creatinine (Cr) ≤1.5×ULN or estimated by Cockcroft-Gault glomerular filtration formula ≥60 mL/min;
      4. Serum albumin (ALB) ≥30g/L.
    3. Urine routine examination standard: urine routine indicates urine protein \<++; if urine protein ≥++, it is necessary to confirm that the 24-hour urine protein quantitative ≤1.0 g.
    4. Blood coagulation test standards: (PT), activated partial thromboplastin time (APTT), international normalized ratio (INR)≤1.5×ULN (no anticoagulant therapy).
    5. Thyroid Stimulating Hormone (TSH) ≤ ULN; if abnormal, T3 and T4 levels should be examined. If T3 and T4 levels are normal, it can be selected.
    6. Heart color Doppler ultrasound assessment: (LVEF) ≥50%.
    7. 12-lead evaluation: \<450ms (male), QTc\<470ms (female).
  • Women of childbearing age should agree to use effective measures during the study period and 6 months after the end of the study, and have a negative serum pregnancy test within 7 days before the study enrollment; men should agree to the study period and 6 months after the end of the study period Effective contraceptive measures must be used internally.
  • The subjects voluntarily joined the study, signed the form, and had good compliance.

Exclusion criteria

Exclusion Criteria:

  • Tumor disease and medical history:

    1. exists before enrollment. Subjects meeting one of the following requirements can be included;

      1. Have received brain metastasis treatment (surgery/radiotherapy) in the past and meet all the following criteria:

        • only supratentorial and cerebellar metastasis,
        • the condition needs to be stable for ≥ 2 weeks and no imaging evidence of new brain metastasis or brain metastasis expansion is found;
        • there is no brain metastasis symptom, and the subject must have stopped using /dehydrators for at least 2 weeks before starting to use the trial drug;
      2. The patient has not received brain metastasis treatment in the past and meets all the following criteria:

        • the maximum diameter of the lesion is less than 2cm;
        • the condition needs to be stable for ≥ 2 weeks (no imaging evidence of new brain metastasis or expanded brain metastasis is found), and there is no neurological symptoms caused by brain tissue compression;
        • the subject must have stopped using corticosteroids/dehydrating agents for at least 2 weeks before starting to use the test drug;
    2. There are midbrain, pons, medulla oblongata, spinal cord and meningeal metastases;
    3. Other malignant tumors appeared or were present within 3 years. The following two cases can be included: other malignant tumors treated by single operation have achieved 5-year Disease-free survival (DFS) in a row; The cured cervical carcinoma in situ, non melanoma skin cancer and superficial bladder tumor [ta (non-invasive tumor), tis (carcinoma in situ) and T1 (tumor infiltrating basement membrane)];
    4. Central type, cavity squamous cell carcinoma (primarily in the main bronchus and around the hilar);Imaging shows that the tumor invades large blood vessels or is unclearly separated from the blood vessels, or the investigator judges that the tumor is likely to invade important blood vessels and cause fatal bleeding during the subsequent study(The major vessels in the chest include pulmonary aorta, left pulmonary artery, right pulmonary artery, four pulmonary veins, superior vena cava, inferior vena cava and aorta);
    5. There is spinal cord compression and/or severe bone injury caused by tumor bone metastasis, including pathological fracture and severe bone pain with poor control;
    6. Patients with serous cavity (thoracic cavity, abdominal cavity, or pericardial cavity) that require repeated drainage to relieve clinical symptoms (as determined by the investigator), or who have received drainage of serous cavity effusion for the purpose of treatment within 2 weeks before treatment.
  • Previous anti-tumor treatments:

    1. Received the treatment of proprietary Chinese medicines with anti-tumor indications specified in the China National Medical Products Administration (NMPA) approved drug instructions within 2 weeks before the start of the study treatment(Including compound cantharidin capsules, Kangai injection, Kanglaite capsule/injection, Aidi injection, brucea javanica oil injection/capsule, Xiaoaiping tablet/injection, Huachansu capsule, etc.);
    2. Previously received related immunotherapy drugs for programmed death 1 (), PD-L1, cytolytic T lymphocyte-associated antigen-4 (CTLA-4), etc.;
    3. Previous use of anti-angiogenic drugs such as bevacizumab, anlotinib, apatinib, lenvatinib, sorafenib, sunitinib, regorafenib, fruquintinib, etc.;
    4. Failure to recover from the toxicity and/or complications of previous interventions to ≤1, except for hair loss and peripheral neuropathy ≤2;
  • Combined diseases and medical history:

    1. Liver cirrhosis, active hepatitis*;(Note: active hepatitis ( reference: HBV-DNA > 1*103 copy /mL or > 2000IU/mL) when HBsAg is positive. reference: Hepatitis C virus (HCV) antibody is positive, and HCV titer detection value exceeds the value);
    2. Renal abnormalities: i.Renal failure requires hemodialysis or peritoneal dialysis; ii.Previous or existing nephrotic syndrome, chronic nephritis.
    3. Cardiovascular and cerebrovascular abnormalities:

      1. Patients with previous or present heart failure, degree II or above heart block:
      2. Myocardial infarction or unstable angina, supraventricular or ventricular arrhythmia with clinical significance need treatment or intervention;
      3. Vascular embolism and cerebrovascular accident (including , cerebral hemorrhage and cerebral infarction) occurred within 9 months( Prophylactic use of anticoagulant therapy is allowed for patients with thrombotic tendency or undergoing anticoagulant therapy.)
      4. After more than two kinds of drug treatment, blood pressure control is still not ideal (systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 90 mmHg).
    4. Gastrointestinal abnormalities:

      1. Inability to take medications (such as inability to swallow, intestinal obstruction, etc.);
      2. A history of malabsorption syndrome or other diseases that interfere with gastrointestinal absorption;
      3. Received treatment for active peptic ulcer in the past 6 months;
      4. Despite the maximum medical treatment, chronic diarrhea of grade 2 and above continues to occur;
      5. Other conditions determined by the researcher that may cause gastrointestinal bleeding and perforation.
    5. History of immunodeficiency:

      1. Have a history of immunodeficiency, including positive or other acquired or congenital immunodeficiency diseases;
      2. Active disease or history of autoimmune disease, including but not limited to Crohn's disease, ulcerative colitis, autoimmune hepatitis/enteritis/vasculitis/nephritis, etc.
      3. Prepare to undergo or have previously received an organ transplant;
      4. Patients who require systemic or topical therapy to achieve immunosuppressive purposes and need to continue to use them within two weeks before randomization (except for glucocorticoid daily dose \<10 mg prednisone or other equivalent hormones). (Note: Hormone replacement therapy (such as thyroxine, insulin, or physiological corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered as systemic therapy and allowed to be used.)
    6. Bleeding risk:

      1. Suffered from bleeding or coagulopathy within 28 days before the start of treatment or was using warfarin, aspirin and other antiplatelet agglutination drugs (except for aspirin ≤100 mg/d preventive drugs);
      2. Had hemoptysis >2.5 mL/day in 28 days before the start of treatment;
      3. Regardless of the severity, patients with any history of bleeding or coagulopathy;
      4. Received major surgical treatment, open , etc. within 28 days before the start of the study treatment;
      5. Long-term unhealed wounds or fractures, except for pathological fractures;
    7. Poor control of type I diabetes or II diabetes (fasting blood glucose (FBG)> 10mmol/L);
    8. Severe infections within 4 weeks before the start of study treatment, including but not limited to hospitalization due to bacteremia, severe pneumonia, or other severe infections; subjects with ≥ grade 2 active infections within 4 weeks before the start of study treatment Or fever of unknown cause occurred during the screening period and before the first administration>38.0℃;
    9. Past or existing pneumoconiosis, interstitial pneumonia, (non-infectious) pneumonia that requires adrenal corticosteroid therapy, currently suffering from other types of pneumonia ≥2, or lung function tests confirmed severely impaired lung function ( (FEV1) or diffusing capacity of lung for carbon monoxide(DLCO) or DLCO per alveolar volume (DLCO /VA) accounts for the expected value %\<40%) and other objective evidence;
    10. Patients with active tuberculosis within 1 year before enrollment; subjects with a history of active pulmonary tuberculosis infection 1 year ago must provide clear evidence of cure before enrollment; if tuberculosis is suspected during the screening period, chest radiographs and sputum must be passed Enter the group only after the liquid and clinical symptoms are eliminated;
    11. Allergies, or a history of severe allergies in the past, or severe reactions after receiving other monoclonal antibody treatments, or known allergies to the ingredients of the study drug ;
    12. Previous history of severe mental disorders;
    13. People with a history of drug abuse, alcohol or drug abuse;
  • The end of the previous clinical study (last dose) is less than 4 weeks or the study drug's 5 half-lives, whichever is shorter.
  • vaccination history within 28 days before randomization or planned live attenuated vaccination during the study period. Seasonal influenza vaccine for injection is usually an inactivated virus vaccine and is allowed to be vaccinated during the study period.
  • Female patients during pregnancy or lactation.
  • For patients with known epidermal growth factor receptor (EGFR) sensitive mutation, anaplastic lymphoma kinase (ALK) fusion and ROS proto-oncogene 1 (ROS1) fusion, detection is not mandatory for those with unknown gene status
  • According to the investigator's point of view, it may increase the risks associated with participating in the study, or other severe, acute or chronic medical diseases or laboratory abnormalities that may interfere with the interpretation of the study results, or other reasons that are not suitable for participating in this clinical study.
Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
570 participants (estimated)

Study arms

  • Experimental
    TQB2450 Injection and Anlotinib Hydrochloride Capsules

    In the induction stage: TQB2450 injection: 1200 mg, Intravenous drip on d1; Carboplatin injection: Area Under Curve 5mg/mL/min, Intravenous drip on d1; Paclitaxel injection: 175mg/m2, Intravenous drip on d1. The above schemes are repeated every three weeks. In the maintenance stage: TQB2450 injection: 1200 mg, Intravenous drip on d1; Anlotinib Hydrochloride Capsules: 10mg, orally administered every day from d1-d14. The above schemes are repeated every three weeks.

    Drug: TQB2450 · Drug: Anlotinib hydrochloride capsule

  • Active comparator
    Tislelizumab Injection

    In the induction stage: Tislelizumab injection: 200 mg, Intravenous drip; Carboplatin injection: Area Under Curve 5mg/mL/min, Intravenous drip; Paclitaxel injection: 175mg/m2, Intravenous drip. The above schemes are repeated every three weeks. In the maintenance stage: Tislelizumab injection: 200 mg, Intravenous drip on d1 Placebo capsule: 0mg, orally administered every day from d1-d14. The above schemes are repeated every three weeks.

    Drug: Tislelizumab injection

Interventions

  • TQB2450 is a humanized monoclonal antibody targeting the programmed death ligand 1 (PD-L1), which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, making T cells recover their activity, thereby enhancing the immune response.

  • Anlotinib hydrochloride is a multi-target receptor tyrosine kinase inhibitor, which can target angiogenesis related kinases, such as VEGFR 1/2/3, FGFR 1/2/3 and other tumor cell proliferation related kinases like Platelet-derived growth factor receptor (PDGFR) α/β、 C-kit, RET.

  • Tislelizumab injection can bind to human programmed cell death 1 (PD-1), a cell membrane protein that is mainly expressed on activated T cells and inhibits T cell activation.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    Progression Free Survival (PFS) assessed by Independent Review Committee (IRC)

    Time frame: Base line up to 2 years. The curative effect was evaluated every 6 weeks (42 days) in the first 54 weeks of treatment period; After 54 weeks, the efficacy was evaluated every 9 weeks (63 days).

Secondary outcomes

  1. Overall survival (OS)

    Overall survival is the time from randomization to the time of death from any cause.

    Time frame: Baseline up to death event, assessed up to 2 years.

  2. Progression free survival (PFS)

    Progression free survival (PFS) assessed by investigators according to The Response Evaluation Criteria In Solid Tumors 1.1 (RECIST) and iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.

    Time frame: From randomization to Progression disease, assessed up to 2 years.

  3. Objective response rate (ORR)

    Objective response rate (ORR), assessed by investigators according to The Response Evaluation Criteria In Solid Tumors 1.1 (RECIST) and iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.

    Time frame: From randomization to Progression disease, assessed up to 2 years.

  4. Disease control rate (DCR)

    Disease control rate (DCR)assessed by investigators according to RECIST 1.1 and iRECIST criteria

    Time frame: From randomization to Progression disease, assessed up to 2 years.

  5. Duration of response (DOR)

    Duration of response (DOR) assessed by investigators according to RECIST1.1 and iRECIST criteria

    Time frame: From randomization to Progression disease, assessed up to 2 years.

  6. The occurrence of all adverse events (AEs)

    The occurrence of adverse events (AEs) is to evaluate safety profile

    Time frame: Baseline up to 2 years.

  7. The severity of all adverse events (AEs)

    The severity of adverse events (AEs) is to evaluate safety profile

    Time frame: Baseline up to 2 years.

  8. The occurrence of abnormal heart rate in 12 lead Electrocardiograph (ECG)

    The occurence of abnormal heart rate is to evaluate safety profile

    Time frame: Baseline up to 2 years.

  9. The severity of abnormal heart rate in 12 lead Electrocardiograph (ECG)

    The severity of abnormal heart rate is evaluated in accordance with the standard of common toxic reactions of the National Cancer Institute \[NCI CTC v5.0\].

    Time frame: Baseline up to 2 years.

  10. The occurrence of abnormal PR interval in 12 lead ECG

    The occurrence rate of abnormal 12 lead ECG is to evaluate safety profile. The results of PR interval were divided into low, normal and high according to the normal value range.

    Time frame: Baseline up to 2 years.

  11. The severity of abnormal PR interval in 12 lead ECG

    The results of PR interval were divided into low, normal and high according to the normal value range, and the relative baseline change was described with a cross table. The minimum or maximum observed value after the baseline is used to calculate the results after the baseline. Descriptively summarize the results of PR examination at each visit, classify them as normal, abnormal without clinical significance, and abnormal with clinical significance, and compare them with the results of baseline, and describe them with cross classification table. The severity is evaluated in accordance with the standard of common toxic reactions of the National Cancer Institute \[NCI CTC v5.0\]

    Time frame: Baseline up to 2 years.

  12. The occurrence of abnormal QRS interval in 12 lead ECG

    The occurrence of abnormal 12 lead ECG is to evaluate safety profile. The QRS interval results were divided into low, normal and high according to the normal value range.

    Time frame: Baseline up to 2 years.

  13. The severity of abnormal QRS interval in 12 lead ECG

    The QRS interval results were divided into low, normal and high according to the normal value range, and the relative baseline change was described with a cross table. The minimum or maximum observed value after the baseline is used to calculate the results after the baseline. Descriptively summarize the results of PR examination at each visit, classify them as normal, abnormal without clinical significance, and abnormal with clinical significance, and compare them with the results of baseline, and describe them with cross classification table. The severity is evaluated in accordance with the standard of common toxic reactions of the National Cancer Institute \[NCI CTC v5.0\]

    Time frame: Baseline up to 2 years.

  14. The occurrence of abnormal QT interval in 12 lead ECG

    The occurrence rate of Abnormal 12 lead ECG is to evaluate safety profile. The results of QT interval were divided into low, normal and high according to the normal value.

    Time frame: Baseline up to 2 years.

  15. The severity of abnormal QT interval in 12 lead ECG

    The results of QT interval were divided into low, normal and high according to the normal value range, and the relative baseline change was described with a cross table. The minimum or maximum observed value after the baseline is used to calculate the results after the baseline. Descriptively summarize the results of PR examination at each visit, classify them as normal, abnormal without clinical significance, and abnormal with clinical significance, and compare them with the results of baseline, and describe them with cross classification table. The severity is evaluated in accordance with the standard of common toxic reactions of the National Cancer Institute \[NCI CTC v5.0\]

    Time frame: Baseline up to 2 years.

  16. The occurrence of abnormal QTc interval in 12 lead ECG

    The occurrence of Abnormal 12 lead ECG is to evaluate safety profile. The results of QTc interval were divided into low, normal and high according to the normal value.

    Time frame: Baseline up to 2 years.

  17. The severity of abnormal QTc interval in 12 lead ECG

    The results of QTc interval were divided into low, normal and high according to the normal value range, and the relative baseline change was described with a cross table. The minimum or maximum observed value after the baseline is used to calculate the results after the baseline. Descriptively summarize the results of PR examination at each visit, classify them as normal, abnormal without clinical significance, and abnormal with clinical significance, and compare them with the results of baseline, and describe them with cross classification table. The severity is evaluated in accordance with the standard of common toxic reactions of the National Cancer Institute \[NCI CTC v5.0\]

    Time frame: Baseline up to 2 years.

  18. The occurrence of serious adverse events (SAEs)

    The occurrence of serious adverse events (SAEs) is to evaluate safety profile

    Time frame: Baseline up to 2 years.

  19. The severity of serious adverse events (SAEs)

    The severity of serious adverse events (SAEs) is to evaluate safety profile

    Time frame: Baseline up to 2 years.

  20. European organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ-C30)

    QLQ-C30 is a quality of life questionnaire to help understand the physical condition of the subjects. The subjects need to answer them in person and circle the number that best reflects their situation. Among them, 1 represents no, 2 represents a little, 3 represents some, and 4 represents a lot. Questions 29 and 30 need to choose the most suitable number from 1 to 7 and draw a circle. The other 1 represents very poor, and 7 represents very good. Questions 29 and 30 need to choose the most suitable number from 1 to 7 and draw a circle. The other 1 represents very poor, and 7 represents very good.

    Time frame: Baseline up to 2 years.

  21. Quality of life questionnaire lung cancer module (QLQ-LC13)

    QLQ-LC13 is a quality of life questionnaire to help understand the physical condition of the subjects. The subjects need to answer them in person and circle the number that best reflects their situation. Among them, 1 represents no, 2 represents a little, 3 represents some, and 4 represents a lot.

    Time frame: Baseline up to 2 years.

  22. EuroQol Five Dimensions Questionnaire (EQ-5D) assessment pro

    EQ-5D assessment pro is a quality of life questionnaire, which has five questions that need to be answered by the subjects themselves, choose the answer that best reflects their health, and mark the point on the set scale that best represents their health, of which 100 represents the best condition and 0 represents the worst condition.

    Time frame: Baseline up to 2 years.

  23. Incidence of Antidrug antibody

    It's a parameter to evaluate the immunogenicity of TQB2450 injection

    Time frame: Baseline up to 2 years.

  24. Incidence of neutralizing antibody

    It's a parameter to evaluate the immunogenicity of TQB2450 injection

    Time frame: Baseline up to 2 years.

07

Study locations

4 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2023; primary completion for Oct 2024, 20 months later.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 20 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2022
First posted
Feb 8, 2023
StartEst.
Feb 2023
Primary completionEst.
Oct 2024
CompletionEst.
Oct 2025
Last update
Feb 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05718167
Responsible party
Sponsor
First posted
Feb 8, 2023
Start date
Feb 2023 (estimated)
Primary completion
Oct 2024 (estimated)
Completion
Oct 2025 (estimated)
Last update
Feb 14, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benmelstobart

Start the discussion